Depomed (DEPO): Raising PT 30% But Keeping Neutral Rating - UBS

October 3, 2016 8:06 AM EDT
Get Alerts DEPO Hot Sheet
Price: $23.37 -1.68%

Rating Summary:
    10 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 26 | Down: 29 | New: 38
Trade DEPO Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

UBS analyst, Ami Fadia, reiterated her Neutral rating on shares of DepoMed Inc (NASDAQ: DEPO) but raised her price target to $26.00 from $20.00 after the the District Court of New Jersey upheld the validity of all three of the Nucynta litigated patents. The court also ruled that all of the three generic filers infringe two of the three patents, i.e., the '593 (method of preparation, 8/5/2022 expiry) and '364 (polymorph, expiring 6/27/2025) patents. However, regarding the third patent, '130 expiring 9/22/2028, the judge ruled that Actavis and Roxane did not infringe this patent while Alkem infringed claims 1, 2, 3, and 6.

The next catalyst for the stock is the upcoming shareholder special meeting on November 15.

For an analyst ratings summary and ratings history on DepoMed Inc click here. For more ratings news on DepoMed Inc click here.

Shares of DepoMed Inc closed at $24.97 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities


Add Your Comment